Radius Health Inc  

(Public, NASDAQ:RDUS)   Watch this stock  
Find more results for RDUS
38.95
+1.24 (3.29%)
After Hours: 38.95 0.00 (0.00%)
Feb 22, 4:48PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.40 - 39.29
52 week 24.66 - 49.16
Open 38.06
Vol / Avg. 1.34M/856,352.00
Mkt cap 1.74B
P/E     -
Div/yield     -
EPS -5.43
Shares 44.59M
Beta 1.21
Inst. own 126%
Mar 1, 2018
Q4 2017 Radius Health Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 22, 2018
Radius Health Inc at RBC Capital Markets Healthcare Conference
Feb 15, 2018
Radius Health Inc at Leerink Partners Global Healthcare Conference
Jan 8, 2018
Radius Health Inc at JPMorgan Healthcare Conference - Webcast
Dec 7, 2017
Radius Health Inc Oncology Program Update from San Antonio Breast Cancer Symposium - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -429.45% -
Operating margin -413.57% -
EBITD margin - -
Return on average assets -62.17% -44.44%
Return on average equity -90.42% -47.58%
Employees 229 -
CDP Score - -

Address

950 Winter St
WALTHAM, MA 02451-1424
United States - Map
+1-617-5514000 (Phone)
+1-617-5514701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

Officers and directors

Kurt C. Graves Independent Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Jesper Hoiland President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Jose Carmona Chief Financial Officer, Principal Accounting Officer, Treasurer
Age: 45
Bio & Compensation  - Reuters
Gary Hattersley Ph.D. Senior Vice President, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Brent Hatzis-Schoch Senior Vice President, General Counsel, Secretary
Age: 52
Bio & Compensation  - Reuters
Lorraine A. Fitzpatrick M.D. Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Gregory Williams Ph.D. Chief Development Officer
Age: 58
Bio & Compensation  - Reuters
Willard H. Dere M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Age: 56
Bio & Compensation  - Reuters
Jean-Pierre Garnier Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters